Neuronetics Inc
(STU:NRC)
€
1.388
-0.034 (-2.39%)
Market Cap: 80.76 Mil
Enterprise Value: 107.31 Mil
PE Ratio: 0
PB Ratio: 4.82
GF Score: 52/100 Neuronetics Inc at JMP Securities Life Sciences Conference Transcript
May 16, 2023 / 04:30PM GMT
Release Date Price:
€2.5
(-0.40%)
Daniel Stauder
JMP Securities LLC - Analyst
Welcome to day two of the JMP Life Sciences Conference. I'm pleased to introduce members of Neuronetics management team. We have CEO, Keith Sullivan; CFO, Steve Furlong. Before we get into it, just as a reminder, Neuronetics is a leader in the TMS space, treating a range of neurological disorders, primarily major depressive disorder.
Questions & Answers
Daniel Stauder
JMP Securities LLC - Analyst
So just with that, let's get going. Keith, you've been at the helm for almost three years now. We would love to hear your high-level perspective on where the TMS market stands right now, what has changed in the industry since you've joined, and where Neuronetics stands within that today.
Keith Sullivan
Neuronetics, Inc. - President & CEO
Very good. Well, thanks for having us.
Daniel Stauder;Keith Sullivan
JMP Securities LLC - Analyst;Neuronetics, Inc. -
Of course. Thank you for coming.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot